BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3141845)

  • 1. [Blood platelet changes in myeloproliferative disorders].
    D'Angelo G; Calvano D; Giardini C
    Minerva Med; 1988 Oct; 79(10):853-7. PubMed ID: 3141845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
    Wehmeier A; Südhoff T; Meierkord F
    Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
    Murphy S; Davis JL; Walsh PN; Gardner FH
    Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defective platelet beta-N-acetyl hexosaminidase content and release in chronic myeloproliferative disorders.
    Emiliani C; Ciferri S; Mencarelli S; Mezzasoma AM; Momi S; Orlacchio A; Gresele P
    Platelets; 2006 Feb; 17(1):20-9. PubMed ID: 16308183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes.
    Finazzi G; Budde U; Michiels JJ
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():71-8. PubMed ID: 8951775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders.
    Pareti FI; Gugliotta L; Mannucci L; Guarini A; Mannucci PM
    Thromb Haemost; 1982 Apr; 47(2):84-9. PubMed ID: 7101243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased response to arachidonic acid and U-46619 and resistance to inhibitory prostaglandins in patients with chronic myeloproliferative disorders.
    Cortelazzo S; Galli M; Castagna D; Viero P; de Gaetano G; Barbui T
    Thromb Haemost; 1988 Feb; 59(1):73-6. PubMed ID: 3129810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
    Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
    Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal aggregation and increased size of platelets in myeloproliferative disorders.
    Cortelazzo S; Barbui T; Bassan R; Dini E
    Thromb Haemost; 1980 Jun; 43(2):127-30. PubMed ID: 7455970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet abnormalities in myeloproliferative disorders.
    Holme S; Murphy S
    Clin Lab Med; 1990 Dec; 10(4):873-88. PubMed ID: 2272179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet adhesion.
    Packham MA; Mustard JF
    Prog Hemost Thromb; 1984; 7():211-88. PubMed ID: 6397767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood platelet calcium content and aggregation behaviour in myeloproliferative disorders and secondary thrombocytosis.
    Mindner K; Ostermann G; Hochhaus A; Höche D; Till U
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):461-4. PubMed ID: 2465953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Shortening of acetylsalicylic acid-prolonged bleeding time by means of desmopressin].
    Beck KH; Bleckmann U; Mohr P; Kretschmer V; Huss B
    Beitr Infusionsther Transfusionsmed; 1994; 32():437-9. PubMed ID: 9480140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet membrane fatty acids in thrombocytosis due to myeloproliferative disorders.
    Leoncini G; Maresca M; Balestrero F; Benatti U; Armani U; Piana A
    Cell Biochem Funct; 1984 Jan; 2(1):23-5. PubMed ID: 6467512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders.
    Malpass TW; Savage B; Hanson SR; Slichter SJ; Harker LA
    J Lab Clin Med; 1984 Jun; 103(6):894-904. PubMed ID: 6233383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine.
    Di Minno G; Cerbone AM; Mattioli PL; Turco S; Iovine C; Mancini M
    J Clin Invest; 1985 Feb; 75(2):328-38. PubMed ID: 3156146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet abnormalities in idiopathic myelofibrosis: functional, biochemical and immunomorphological correlations.
    Leoni P; Rupoli S; Lai G; Brunelli MA; Belmonte MM; Pugnaloni A; Rabini RA; Mazzanti L; Biagini G
    Haematologica; 1994; 79(1):29-39. PubMed ID: 15378946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathobiology of animal platelets.
    Meyers KM
    Adv Vet Sci Comp Med; 1985; 30():131-65. PubMed ID: 3004158
    [No Abstract]   [Full Text] [Related]  

  • 20. Platelet unresponsiveness to collagen: involvement of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder.
    Handa M; Watanabe K; Kawai Y; Kamata T; Koyama T; Nagai H; Ikeda Y
    Thromb Haemost; 1995 Mar; 73(3):521-8. PubMed ID: 7667837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.